DOI: 10.1097/01.BONEJ.0000361452.24000.80

,  

Issn Print: 1938-8659

Publication Date: 2009/10/01


Print

BMD Monitoring and Alendronate Treatment: Little Value Found in Early Monitoring

    loading  Checking for direct PDF access through Ovid

Excerpt

Monitoring bone mineral density (BMD) in postmenopausal women in the first three years after starting treatment with a potent bisphosphonate (alendronate) is unnecessary and may be misleading, according to a new study. (See Bell et al., 2009.) Researchers, including Katy J. L. Bell, Research Fellow at the School of Public Health, Univer-sity of Sydney, Sydney, Australia, and colleagues at the University of Sydney and at the Univer-sity of Minnesota Medical School and the University of California in the United States, recommend that routine monitoring should be avoided in this early period after alendronate treatment is commenced.
    loading  Loading Related Articles